SITC Sets Sept. 3-4 Lausanne Session on Immune Cell Engagers for Cancer
Updated
Updated · Oncodaily · Jun 23
SITC Sets Sept. 3-4 Lausanne Session on Immune Cell Engagers for Cancer
1 articles · Updated · Oncodaily · Jun 23
Summary
Sept. 3-4 is when SITC will hold a Lausanne, Switzerland, learning session focused on immune cell engagers in cancer treatment.
Anna Farago, MD, PhD, is slated to lead the program, which SITC said will examine how the therapies are advancing and what they could mean for patients and drug developers.
LinkedIn carried the announcement, framing immune cell engagers as a fast-evolving treatment approach and positioning the event as an educational update on that progress.